Business Context and Reporting Period
This Form 8-K is filed by Aadi Bioscience, Inc. (not Whitehawk Therapeutics, Inc.) on August 10, 2022. The filing serves to announce the company's financial results for the fiscal quarter ended June 30, 2022. The registrant is an emerging growth company incorporated in Delaware, with its principal executive offices in Pacific Palisades, California.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the provided text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It solely references the issuance of a press release containing the quarterly results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished in Item 2.02 and Item 9.01 (including the press release) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, the text does not contain specific guidance, management commentary, risks, or contingencies beyond the reference to the external press release.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (Press Release dated August 10, 2022).
- Confirm the company name is Aadi Bioscience, Inc. (Ticker: AADI), as the input metadata incorrectly listed Whitehawk Therapeutics, Inc.
- Review the press release for any updates on clinical trial progress or pipeline developments, which are typical for this sector but not detailed in the 8-K cover text.
- Check the company's cash runway and burn rate in the full press release to assess liquidity status.